Hospital Authority

Company snapshot

Hospital Authority maintains 322 tracked programs across Hepatocellular Carcinoma, Obesity, Acute Kidney Injury, Nasopharyngeal Carcinoma, Coronary Artery Disease, Nasopharyngeal Carcinoma (NPC), Gastric Cancer, Pain Postoperative, Drug Resistant Epilepsy, Alzheimer Disease, Stroke, Acute Respiratory Tract Infections. Momentum score: 20/100 (30-day delta: n/a). Public registry data covers pipeline

• 322 active pipeline program(s) linked via ClinicalTrials.gov.
• 322 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Hospital Authority. Not investment advice.

• Peer + 0 momentum

  Chinese Academy of

  TA overlap score 60

• Peer + 0 momentum

  First People's Hospital

  TA overlap score 50

• Peer + 0 momentum

  Eli Lilly and

  TA overlap score 40

• Peer + 0 momentum

  LianBio

  TA overlap score 25.6

• Peer + 0 momentum

  Sun Yat-sen University

  TA overlap score 23.8

• Peer + 0 momentum

  vTv Therapeutics

  TA overlap score 22.8

• Peer + 0 momentum

  Evidence Based Cataract

  TA overlap score 22

• Peer + 0 momentum

  Chinese PLA General

  TA overlap score 20.8

Recent activity

Latest pipeline, patent, and corporate events for Hospital Authority.

1. Jun 8, 2026 Clinical update

   TCHIRB-970208-E — Phase 3

2. Jun 8, 2026 Clinical update

   Remimazolam_OPCAB — Unknown

3. Jun 8, 2026 Clinical update

   Art-BTC — Phase 2

4. Jun 8, 2026 Clinical update

   201010025M — Approved

5. Jun 8, 2026 Clinical update

   SNUCPT08_GCPGC — Phase 1

View all clinical trial activity →

• What is Hospital Authority?

  Hospital Authority, Hong is a pharma organization headquartered in CN. Primary therapeutic focus areas include Hepatocellular Carcinoma, Obesity, Acute Kidney Injury, Nasopharyngeal Carcinoma, Coronary Artery Disease. NovaPharmaNews links 322 clinical program(s), 0 drug profile(s

• Is Hospital Authority publicly traded?

  Hospital Authority appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Hospital Authority develop or market?

  We link 301 drug profile(s) where Hospital Authority is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/hospital-authority-hong-kong#company-drugs.

• What are the latest developments for Hospital Authority?

  In the last 12 months our linked public records show 322 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Hospital Authority focus on?

  Hospital Authority focuses on Hepatocellular Carcinoma, Obesity, Acute Kidney Injury based on our analysis of their pipeline programs and drug development activities.